In a bipartisan effort to address escalating prescription drug costs, Senators Peter Welch (D-VT) and Josh Hawley (R-MO) have introduced legislation aimed at curbing the use of “patent thickets” by pharmaceutical companies. This practice involves obtaining multiple, overlapping patents to extend market exclusivity and delay the entry of lower-cost generic drugs.
The proposed bill seeks to streamline litigation by allowing brand-name drug manufacturers to assert only one patent per “thicket” in legal actions against generic competitors. This approach is more stringent than previous legislative efforts, such as the Affordable Prescriptions for Patients Act introduced by Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT), which permitted the assertion of a limited group of patents. The Cornyn-Blumenthal bill had garnered unanimous consent in the Senate but ultimately did not become law.
Senator Welch emphasized the detrimental impact of patent thickets on consumers, stating, “For decades, Big Pharma has exploited U.S. courts and the patent system through anticompetitive practices that prevent generic and biosimilar competitors from entering the market, forcing Vermonters to pay more out of pocket for lifesaving drugs.” Senator Hawley echoed this sentiment, highlighting the bipartisan commitment to reforming the patent process to promote competition and reduce drug prices.
The introduction of this legislation reflects a growing consensus among lawmakers to address patent system abuses that contribute to high prescription drug costs. By limiting the strategic use of multiple patents to delay generic competition, the bill aims to foster a more competitive pharmaceutical market, potentially leading to more affordable medications for consumers.
As the bill progresses through the legislative process, it is expected to stimulate further debate on balancing the protection of intellectual property with the need to ensure timely access to cost-effective generic drugs. The outcome of this legislative effort could have significant implications for the pharmaceutical industry and healthcare affordability in the United States.